statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zura Bio Limited (Nasdaq: ZURA) (Zura Bio), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that it...

Zura Bio Announces Oversubscribed $112.5 Million Private Placement

Zura Bio Limited (Nasdaq: ZURA) (Zura Bio) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that Robert Lisicki...

Zura Bio Announces Robert Lisicki as CEO and Director

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Zura Bio price target lowered by $1 at Oppenheimer, here's why

Zura Bio Ltd (ZURA) Aligns with EPS Projections, Net Loss Increases Significantly from Previous YearRelated Stocks: ZURA...

Zura Bio Ltd (ZURA) Reports Full Year 2023 Financial Results Amidst Leadership Transition

An announcement from Zura Bio (ZURA) is now available. ZURA is set to experience a change in leadership as Robert Lisicki takes over as CEO from th...

Zura Bio Announces Leadership Change as New CEO Steps In

Zura Bio names Robert Lisicki as CEO, succeeding Someit Sidhu, M.D.

Zura Bio Limited (Nasdaq: ZURA) (Zura Bio) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023...

Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
ZURA stock results show that Zura Bio missed analyst estimates for earnings per share the fourth quarter of 2023.
The post ZURA Stock...

ZURA Stock Earnings: Zura Bio Misses EPS for Q4 2023

Zura Bio Limited (Nasdaq: ZURA) (Zura Bio) a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced that members...

Zura Bio Announces Participation at March Conferences

Zura Bio Limited (NASDAQ:ZURA  Get Free Report) was the target of a large decline in short interest during the month of January. As of January 31st, there was short interest totalling 328,500...

Zura Bio Limited (NASDAQ:ZURA) Sees Large Decline in Short Interest

Zura Bio Ltd. is a clinical-stage biotechnology company that engages in the development of novel medicines for immune disorders. It focuses on the development of ZB-168, a treatment for Alopecia Areata and other inflammatory diseases. The company was founded by Someit Sidhu on January 18, 2022 and is headquartered in Henderson, NV.

Volume	133,183.00
52-Wk High	$14.00
52-Wk Low	$2.00

ZURA Zura Bio Ltd - Ordinary Shares - Class A

About

Feed

News

Sentiment

Fundamentals